DE

latest development

Investor Relations

Investment History

Investment Overview

  • US $ 20.8 Invested by private investors from 2012 (Founders & VCs)
  • US $ 4.9 Invested by CSO and Innovation Authorities (Non dilutive Grants)
  • In 2019 Max Herzberg and Yochai Richter acquired all shares of the VC group as a management buy out
  • From 2019 the company is funded by shareholders and management investments, mainly by Max Herzberg and Yochai Richter
  • Listed in Hamburg and Stuttgart Stock Exchanges and upgrading to main Bafin authorized German exchange (in process) for further major funding (Phase 2 and 3 for previous projects and present application)
  • Winner of Seal of excellence from Horizon Europe EIC

Analyst Reports

Vidac Pharma Analyst update August 2025

Download PDF

Vidac Pharma Analyst Report June 2025

Download PDF

Vidac Pharma Analyst Report follow-up Nov. 2024

Download PDF

Vidac Pharma Analyst Report follow-up July 2024

Download PDF

Vidac Pharma Analyst report June 2024

Download PDF

Financial Statements

2025

First 6-Months Report 2025

Download PDF

2024

Annual Report 2024

Download PDF

First 6-Months Report 2024

Download PDF

2023

Annual Report 2023

Download PDF

First 6-Months Report 2023

Download PDF

2022

Annual Report 2022

Download PDF

First 6-Months Report 2022

Download PDF

2021

Annual Report 2021

Download PDF
Dr. Max Herzberg
      20-22 Wenlock Road
      London N1 7GU
      United Kingdom
+972 (0)779300647
Total number of issued shares is 51,625,062
TRADING SYMBOL: T9G
WKN: A3DTUQ
ISIN: GB00BM9XQ619
LEI: 875500BCH1T6XX5EUG13

Disclaimer

The following information does not constitute an public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.